CHMP approves Epidyolex for treatment of epilepsy associated with LGS and DS and older
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the(http://) of GW Pharmaannounced in the UK that the EuropeanMedicines(http://Authority (
HTTP://WWW.CHEMDRUG.COM/)product sems(http://Committee recommended approval of the oral liquid preparation for patients aged 2 and over with assisted treatment with Lennox-Gast) syndrome (CHMP)In the United States,FDA(http://approved the cannabidiol oral liquid preparation (product name: Epidiolex) in June 2018 for assisted treatment of LGS and DS-related epilepsy in patients 2 years and olderThe approval makes Epidiolex the first high-purity, plant-sourced cannabinoiddrug (http:// and the first new anti-epileptic drug (AED) In the U.S market, Epidiolex was launched in November 2018 About Epidiolex
Epidiolex is an oral, high-purity CBD extract (http:// liquid formulation, CBD is a non-psychotic ingredient from cannabis plants that has a variety of pharmacological effects on the nervous system Numerous studies have shown that CBD has significant anti-epileptic and anticonvulsant activity, with fewer side effects than existing anti-epileptic drugs In the United States, the FDA has granted Epidiolex the status of an orphan drug for the treatment of LGS and DS for rare pediatric diseases In addition, the FDA granted Epidiolex fast-track status for the treatment of DS In Europe, Epidyolex has also been granted the status of orphan drug for the treatment of LGS and DS by THE EMA
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
